Editors' ChoiceCARDIAC AMYLOIDOSIS

Breaking through the barrier: Finally hope for patients with cardiac amyloidosis

See allHide authors and affiliations

Science Translational Medicine  12 Sep 2018:
Vol. 10, Issue 458, eaav0337
DOI: 10.1126/scitranslmed.aav0337

Abstract

Tafamidis improves survival, reduces hospitalizations, and preserves quality of life and exercise tolerance for patients with cardiac amyloidosis.

View Full Text

Stay Connected to Science Translational Medicine